127 related articles for article (PubMed ID: 37403986)
21. HPV-inactive cell populations arise from HPV16-transformed human keratinocytes after p53 knockout.
Abboodi F; Buckhaults P; Altomare D; Liu C; Hosseinipour M; Banister CE; Creek KE; Pirisi L
Virology; 2021 Feb; 554():9-16. PubMed ID: 33321328
[TBL] [Abstract][Full Text] [Related]
22. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
[TBL] [Abstract][Full Text] [Related]
23. RNA interference against HPV16 E7 oncogene leads to viral E6 and E7 suppression in cervical cancer cells and apoptosis via upregulation of Rb and p53.
Sima N; Wang W; Kong D; Deng D; Xu Q; Zhou J; Xu G; Meng L; Lu Y; Wang S; Ma D
Apoptosis; 2008 Feb; 13(2):273-81. PubMed ID: 18060502
[TBL] [Abstract][Full Text] [Related]
24. CRISPR/Cas9 delivery with one single adenoviral vector devoid of all viral genes.
Ehrke-Schulz E; Schiwon M; Leitner T; Dávid S; Bergmann T; Liu J; Ehrhardt A
Sci Rep; 2017 Dec; 7(1):17113. PubMed ID: 29215041
[TBL] [Abstract][Full Text] [Related]
25. Development of a CRISPR/Cas9 genome editing toolbox for Corynebacterium glutamicum.
Liu J; Wang Y; Lu Y; Zheng P; Sun J; Ma Y
Microb Cell Fact; 2017 Nov; 16(1):205. PubMed ID: 29145843
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of cervical cancer cell growth in vitro and in vivo by lentiviral-vector mediated shRNA targeting the common promoter of HPV16 E6 and E7 oncogenes.
Zhou J; Li B; Peng C; Wang F; Fu Z; Zhou C; Hong D; Ye F; Lü W; Xie X
Antiviral Res; 2013 May; 98(2):305-13. PubMed ID: 23523766
[TBL] [Abstract][Full Text] [Related]
27. CRISPR-Cas9 therapies in experimental mouse models of cancer.
Estêvão D; Rios Costa N; da Costa RG; Medeiros R
Future Oncol; 2018 Aug; 14(20):2083-2095. PubMed ID: 30027767
[TBL] [Abstract][Full Text] [Related]
28. Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing.
Sinclair F; Begum AA; Dai CC; Toth I; Moyle PM
Drug Deliv Transl Res; 2023 May; 13(5):1500-1519. PubMed ID: 36988873
[TBL] [Abstract][Full Text] [Related]
29. Delivery of CRISPR/Cas9 for therapeutic genome editing.
Xu X; Wan T; Xin H; Li D; Pan H; Wu J; Ping Y
J Gene Med; 2019 Jul; 21(7):e3107. PubMed ID: 31237055
[TBL] [Abstract][Full Text] [Related]
30. CRISPR-Cas9-Mediated Genome Editing in Leishmania donovani.
Zhang WW; Matlashewski G
mBio; 2015 Jul; 6(4):e00861. PubMed ID: 26199327
[TBL] [Abstract][Full Text] [Related]
31. A multifunctional non-viral vector for the delivery of MTH1-targeted CRISPR/Cas9 system for non-small cell lung cancer therapy.
Wang Y; Tang Y; Zhao XM; Huang G; Gong JH; Yang SD; Li H; Wan WJ; Jia CH; Chen G; Zhang XN
Acta Biomater; 2022 Nov; 153():481-493. PubMed ID: 36162766
[TBL] [Abstract][Full Text] [Related]
32. Disruption of human papillomavirus 16 E6 gene by clustered regularly interspaced short palindromic repeat/Cas system in human cervical cancer cells.
Yu L; Wang X; Zhu D; Ding W; Wang L; Zhang C; Jiang X; Shen H; Liao S; Ma D; Hu Z; Wang H
Onco Targets Ther; 2015; 8():37-44. PubMed ID: 25565864
[TBL] [Abstract][Full Text] [Related]
33. Application of CRISPR/Cas9 gene editing technique in the study of cancer treatment.
Jiang C; Meng L; Yang B; Luo X
Clin Genet; 2020 Jan; 97(1):73-88. PubMed ID: 31231788
[TBL] [Abstract][Full Text] [Related]
34. A Rationally Designed Semiconducting Polymer Brush for NIR-II Imaging-Guided Light-Triggered Remote Control of CRISPR/Cas9 Genome Editing.
Li L; Yang Z; Zhu S; He L; Fan W; Tang W; Zou J; Shen Z; Zhang M; Tang L; Dai Y; Niu G; Hu S; Chen X
Adv Mater; 2019 May; 31(21):e1901187. PubMed ID: 30957918
[TBL] [Abstract][Full Text] [Related]
35. Delivery of genome editing tools: A promising strategy for HPV-related cervical malignancy therapy.
Aghamiri S; Talaei S; Roshanzamiri S; Zandsalimi F; Fazeli E; Aliyu M; Kheiry Avarvand O; Ebrahimi Z; Keshavarz-Fathi M; Ghanbarian H
Expert Opin Drug Deliv; 2020 Jun; 17(6):753-766. PubMed ID: 32281426
[TBL] [Abstract][Full Text] [Related]
36. Current updates of CRISPR/Cas9-mediated genome editing and targeting within tumor cells: an innovative strategy of cancer management.
Allemailem KS; Alsahli MA; Almatroudi A; Alrumaihi F; Alkhaleefah FK; Rahmani AH; Khan AA
Cancer Commun (Lond); 2022 Dec; 42(12):1257-1287. PubMed ID: 36209487
[TBL] [Abstract][Full Text] [Related]
37. Anti-tumor effects of genetic vaccines against HPV major oncogenes.
Cordeiro MN; Paolini F; Massa S; Curzio G; Illiano E; Duarte Silva AJ; Franconi R; Bissa M; Morghen Cde G; de Freitas AC; Venuti A
Hum Vaccin Immunother; 2015; 11(1):45-52. PubMed ID: 25483514
[TBL] [Abstract][Full Text] [Related]
38. Two Distinct Approaches for CRISPR-Cas9-Mediated Gene Editing in Cryptococcus neoformans and Related Species.
Wang P
mSphere; 2018 Jun; 3(3):. PubMed ID: 29898980
[No Abstract] [Full Text] [Related]
39. Hyperbranched poly(β-amino ester) based polyplex nanopaticles for delivery of CRISPR/Cas9 system and treatment of HPV infection associated cervical cancer.
Gao X; Jin Z; Tan X; Zhang C; Zou C; Zhang W; Ding J; Das BC; Severinov K; Hitzeroth II; Debata PR; He D; Ma X; Tian X; Gao Q; Wu J; Tian R; Cui Z; Fan W; Huang Z; Cao C; Bao Y; Tan S; Hu Z
J Control Release; 2020 May; 321():654-668. PubMed ID: 32114092
[TBL] [Abstract][Full Text] [Related]
40. Development of a CRISPR/Cas9 System for Methylococcus capsulatus
Tapscott T; Guarnieri MT; Henard CA
Appl Environ Microbiol; 2019 Jun; 85(11):. PubMed ID: 30926729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]